XTL Biopharmaceuticals aims to explore drug candidates that extend health. The biopharmaceutical company acquires, develops, and (ideally) commercializes pharmaceuticals. Following the failure of one candidate in 2008, and having licensed out a chronic hepatitis C program to Presidio Pharmaceuticals, XTL is working to rebuild its pipeline of drugs. Its current pipeline includes compounds in development for the treatment of multiple myeloma, Hepatitis C, and schizophrenia. Many of its candidates are reformulations of existing drugs being put to new uses.